Pfizer (PFE) Cost of Revenue (2009 - 2026)

Pfizer (PFE) has reported Cost of Revenue for 18 consecutive years, with $4.1 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Cost of Revenue rose 8.31% year-over-year to $4.1 billion in Q2 2026; TTM through Jun 2026 was $17.1 billion, a 21.87% decrease from a year earlier, with the FY2025 full-year figure at $16.1 billion, down 9.99% from the prior year.
• Cost of Revenue was $4.1 billion for Q2 2026 at Pfizer, up from $3.5 billion in the prior quarter.
• Over five years, Cost of Revenue peaked at $11.9 billion in Q3 2024 and troughed at $2.8 billion in Q1 2025.
• A 5-year average of $5.5 billion and a median of $4.1 billion in 2025 frame the typical range for Cost of Revenue.
• Across the five-year window, Cost of Revenue soared 140.17% in 2022 and sank 65.06% in 2025, its largest moves.
• Over 5 years, Cost of Revenue stood at $8.6 billion in 2022, then retreated by 12.55% to $7.6 billion in 2023, then jumped by 57.9% to $11.9 billion in 2024, then tumbled by 55.85% to $5.3 billion in 2025, then declined by 22.38% to $4.1 billion in 2026.
• The last three Cost of Revenue figures came in at $4.1 billion (Q2 2026), $3.5 billion (Q1 2026), and $5.3 billion (Q4 2025), per Business Quant data.